TRADEMARK AND DOMAIN NAME LICENSE AGREEMENTTrademark and Domain Name License Agreement • February 28th, 2011 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
THIS TRADEMARK AND DOMAIN NAME LICENSE AGREEMENT (this “Agreement”) is made and entered into as of the Effective Date (as hereinafter defined), by and between GlaxoSmithKline LLC, a limited liability company organized under the laws of the State of Delaware, with offices at One Franklin Plaza, 200 N. 16th Street, Philadelphia, PA 19102-1225, U.S.A. (“GSK”), and Biovail Laboratories International SRL, a Barbados International Society with Restricted Liability having a principal place of business at Welches, Christ Church, BB17154, Barbados, West Indies (“Biovail”).
ASSET PURCHASE AGREEMENT by and between BIOVAIL LABORATORIES INTERNATIONAL SRL and GLAXOSMITHKLINE LLC dated as of February 2, 2011Asset Purchase Agreement • February 28th, 2011 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of February 2, 2011 (the “Agreement Date”), is made by and between Biovail Laboratories International SRL, a Barbados international society with restricted liability (“Buyer”), and GlaxoSmithKline LLC, a Delaware limited liability company (“Seller”). Buyer and Seller are collectively referred to herein as “Parties” and individually as a “Party”.
ContractCredit and Guaranty Agreement • February 28th, 2011 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 (this “Amendment”), dated as of December 31, 2010 among VALEANT PHARMACEUTICALS INTERNATIONAL, a Delaware corporation (the “Borrower”), VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (“Parent”) and certain subsidiaries of Borrower and Parent, as guarantors, the lenders party thereto and GOLDMAN SACHS LENDING PARTNERS LLC (“GSLP”), as Administrative Agent (the “Administrative Agent”). Capitalized terms used herein and not defined shall have the meaning set forth in the Credit Agreement (as defined herein).
STOCK PURCHASE AGREEMENT between and among Biovail International S.à.r.l., and the Stockholders of PharmaSwiss SAStock Purchase Agreement • February 28th, 2011 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations
This Stock Purchase Agreement (the “Agreement”) is made as of January 31, 2011, between and among Biovail International S.à.r.l., a Luxembourg corporation, with its registered address at 208, Val des Bons Malades, L-2121 Luxembourg (the “Purchaser”) and the stockholders of PharmaSwiss SA, a Swiss corporation, with its registered address at Bundesplatz 1, CH-6300 Zug, Switzerland (the “Company”) identified on Schedule A (collectively, the “Sellers” and each a “Seller”, Seller 1, Seller 2, and Seller 3, collectively, the “Founders” and each a “Founder”, and Seller 4 and Seller 5, collectively, the “Financial Investors”, and each a “Financial Investor”).
ContractPurchase Agreement • February 28th, 2011 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
PURCHASE AGREEMENT dated as of February 24, 2011 (this “Agreement”) by and between ValueAct Capital Master Fund, L.P. (the “Seller”) and Valeant Pharmaceuticals International, Inc. (the “Company”).
